62,666
edits
Changes
no edit summary
|-
| 2016 (December) || || || Study || A study finds the {{w|rVSV-ZEBOV vaccine}} against {{w|Ebola virus disease}} to be 95-100% effective, making it the first proven vaccine against the disease.<ref name="TL-20161222">{{cite journal |vauthors=Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP|display-authors=6 |title=Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) |journal = Lancet |volume = 389 |issue = 10068 |pages = 505–518 |year = 2017 |pmid = 28017403 |pmc = 5364328 |doi = 10.1016/S0140-6736(16)32621-6 }}</ref><ref name="CNN-2016122">{{cite news |last=Berlinger |first=Joshua |title=Ebola vaccine gives 100% protection, study finds |url=http://www.cnn.com/2016/12/22/health/ebola-vaccine-study/index.html |date=22 December 2016 |work=[[CNN]] |accessdate=25 April 2018}}</ref> ||
|-
| 2018 || April 20 || {{w|Hepatitis B}} || Recommendation || "CDC published ACIP recommendations for use of hepatitis B vaccine with a novel adjuvant [Heplisav-B]."<ref>{{cite web |last1=Schillie |first1=Sarah |last2=Harris |first2=Aaron |last3=Link-Gelles |first3=Ruth |last4=Romero |first4=José |last5=Ward |first5=John |last6=Nelson |first6=Noele |title=Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant |url=https://www.cdc.gov/mmwr/volumes/67/wr/mm6715a5.htm |website=cdc.gov |accessdate=1 June 2020}}</ref> ||
|-
| 2018 || June 8 || {{w|Influenza}} || Recommendation || "CDC published ACIP's recommendations for the use of quadrivalent live attenuated influenza vaccine (LAIV4) in the 2018–19 influenza season."<ref>{{cite web |last1=Grohskopf |first1=Lisa A. |last2=Sokolow |first2=Leslie Z. |last3=Fry |first3=Alicia M. |last4=Walter |first4=Emmanuel B. |last5=Jernigan |first5=Daniel B. |title=Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) — United States, 2018–19 Influenza Season |url=https://www.cdc.gov/mmwr/volumes/67/wr/mm6722a5.htm |website=cdc.gov |accessdate=1 June 2020}}</ref> ||
